Krystal Biotech to File IND Application for KB103 to Treat Dystrophic Epidermolysis Bullosa – Epidermolysis Bullosa News
Epidermolysis Bullosa News |
Krystal Biotech to File IND Application for KB103 to Treat Dystrophic Epidermolysis Bullosa
Epidermolysis Bullosa News Dystrophic epidermolysis bullosa is an inherited disease characterized by defective production of collagen fiber in the skin. The condition is caused by genetic mutations in the COL7A1 genes. Krystal is developing KB103 to specifically correct this … |
